Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $20 from $18 and keeps a Buy rating on the shares. The firm is “impressed” by the Phase 3 VALOR data of brepocitinib in dermatomyositis. The “fast and durable improvement across broad disease symptoms in brepo-treated patients is particularly significant,” the analyst tells investors in a research note. H.C. Wainwright thinks brepocitinib is well positioned to become the first targeted therapy dermatomyositis in 2027.